Evaluation of the QTc interval during lenvatinib treatment in radioiodine-refractory differentiated thyroid cancer: reports from the real-life clinical practice

As for other tyrosine kinase inhibitors, a prolongation of ECG-recorded QTc intervals may be observed during lenvatinib treatment; a warning on this phenomenon has been stated. However, methods and frequency of ECG recordings have seldom been reported in this context. We present two cases of patient...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2019-08, Vol.15 (24s), p.7-12
Main Authors: Marina, Michela, Serra, Maria Francesca, Rio, Paolo Del, Ceresini, Graziano
Format: Article
Language:English
Subjects:
Blood pressure
Cancer therapies
case report
Case reports
Combined Modality Therapy
Drug dosages
Drug withdrawal
ECG
Electrocardiography
Fentanyl
Heart rate
Heart Ventricles - drug effects
Heart Ventricles - physiopathology
Humans
Hypertension
Iodine Radioisotopes - administration & dosage
lenvatinib
Lymphatic system
Male
Medical imaging
Metastasis
Middle Aged
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - pathology
Neoplasm Recurrence, Local - radiotherapy
Neoplasm Recurrence, Local - surgery
Patients
Phenylurea Compounds - administration & dosage
Phenylurea Compounds - adverse effects
Potassium
Progression-Free Survival
Quinolines - administration & dosage
Quinolines - adverse effects
Thyroid cancer
Thyroid Neoplasms - drug therapy
Thyroid Neoplasms - pathology
Thyroid Neoplasms - radiotherapy
Thyroid Neoplasms - surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As for other tyrosine kinase inhibitors, a prolongation of ECG-recorded QTc intervals may be observed during lenvatinib treatment; a warning on this phenomenon has been stated. However, methods and frequency of ECG recordings have seldom been reported in this context. We present two cases of patients treated with lenvatinib for radioiodine-refractory differentiated thyroid cancer in whom the QTc interval was long monitored through a weekly 12-lead ECG registration. Overall, the maximum QTc increase above baseline was 3 and 31 ms in the first and second patient, respectively. QTc interval did not reach the toxicity value for drug withdrawal in either of the patients. These data may provide further information on cardiac safety profile of lenvatinib in a real-life practice.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2019-0096